吸入性三联药物治疗慢性阻塞性肺疾病研究进展

Research progress of inhalation triple drug therapy for chronic obstructive pulmonary disease

通常情况下,慢性阻塞性肺疾病的患者在临床上的主要表现是持续性的呼吸道症状与气流的受限,而一旦发生了慢性阻塞性肺疾病的急性加重,则很有可能致使肺功能出现逐渐的恶化,患者的生活质量也会不断下降。临床对于慢性阻塞性肺疾病常采取吸入性三联药物疗法,能够有效治疗慢性阻塞性肺疾病,还能够起到一定的预防作用。根据2019年慢性阻塞性肺疾病的定义指出,支气管舒张剂是慢性阻塞性肺疾病药物治疗的基础,包括了长效的抗胆碱能药物和长效β2-受体激动剂。作用机制与作用时间对于不同的支气管舒张剂起到了协同的作用,提高了治疗的效果,减少了不良反应。临床应用的三联药物中包括吸入性糖皮质激素,长效胆碱类的药物及长效β2-受体激动剂,由于不同的药物具备有差异性的作用机制,三者有协同互补的效果。基于此,本文对于慢性阻塞性肺疾病患者采取吸入性三联药物治疗的研究进行综述,以期为慢性阻塞性肺疾病的临床治疗提供帮助。

Usually, the main clinical manifestations of patients with chronic obstructive pulmonary disease are persistent respiratory symptoms and airflow restriction. Once the acute exacerbation of chronic obstructive pulmonary disease occurs, it is likely to lead to the gradual deterioration of pulmonary function and the continuous decline of patients’ quality of life. Inhalation triple drug therapy is often used in clinic for chronic obstructive pulmonary disease, which can not only effectively treat chronic obstructive pulmonary disease, but also play a certain preventive role. According to the definition of chronic obstructive pulmonary disease in 2019, bronchodilators are the basis of drug treatment of chronic obstructive pulmonary disease, including long-acting anticholinergic drugs and long-acting drugs β2-receptor agonists. The mechanism and time of action play a synergistic role for different bronchodilators,improve the therapeutic effect and reduce adverse reactions. The triple drugs in clinical application include inhaled glucocorticoids, long-acting choline drugs and drugs with long-acting effect β2-receptor agonists,which have synergistic and complementary effects because different drugs have different action mechanisms. Based on this, this paper reviews the research progress of inhalation triple drug therapy in patients with chronic obstructive pulmonary disease, in order to provide help for the clinical treatment of chronic obstructive pulmonary disease.